ReviewCell biology and toxicology2025
Tumor-mediated remote regulation of peripheral blood platelets.
Review in Cell biology and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- "Prognostic Significance of Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and Monocyte-to-Lymphocyte Ratios in Myeloid Neoplasms: A Systematic Review".Health science reports · 2026Review
- Peripheral hematological landscapes as biomarkers for detecting postoperative progression in glioblastoma multiforme: a multivariable risk scoring approach.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of platelets in blood coagulation and vascular repair is well known. In recent years, extensive attention has been given to the fact that the impact of tumors on peripheral blood platelets plays a key role in cancer progression. This review systematically summarizes the latest research progress on how tumors regulate the quantity, volume, composition, and activation status of peripheral blood platelets through multiple mechanisms. First, tumor cells can induce excessive platelet production by activating AhR-RUNX1 signaling through paracrine pathways and the release of kynurenine, thereby leading to thrombocytosis, which is associated with advanced tumor stages, metastasis, and poor prognosis. Second, tumor progression may trigger disseminated intravascular coagulation (DIC) or chemotherapy-related bone marrow suppression, which in turn results in consumptive thrombocytopenia. In addition, dynamic changes in the mean platelet volume (MPV) are related to tumor type and progression stage, which may reflect abnormal megakaryocyte differentiation or inflammatory status. In terms of platelet composition, tumor cells can remodel the proteome and transcriptome of platelets by secreting ADP, IgG, and functional RNA. Changes in RNA profiles have been confirmed to have potential for tumor diagnosis. In terms of activation status, tumor cells can induce platelet activation and aggregation (TCIPA) by releasing procoagulant factors such as tissue factors and exosomes (EVs), accelerating thrombosis and promoting angiogenesis. In clinical applications, platelet-related biomarkers have become a research hotspot for early cancer diagnosis and prognostic evaluation. Moreover, targeting platelets affected by tumors provides new strategies for tumor treatment. On the basis of the scientific findings of numerous existing studies, it is speculated that there seems to be a "dynamic balance" among platelets, which also provides a new direction for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.